Last checked at 19 Oct 2010 13:08
| For Immediate Release | 19 October 2010 |
ImmuPharma plc
Update on Phase IIa Clinical Trial with Cancer Compound IPP-204106
ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce that at today's analyst briefing, Dr Robert Zimmer, Chief Scientific Officer, will give the following update on ImmuPharma's exciting Cancer programme IPP-204106, the summary of which is detailed below:
Key Highlights:
·; Dose escalating open label study commenced in patients with at least one treatment failure according to standard regulatory guidelines;
·; The study was designed to show safety and tolerability and assess the maximum tolerated dose;
·; Patients are dosed with an initial dose of 40 mg/sq.m. or 1 mg/kg and if stabilisation or improvement occurs, then patients continue treatment for an additional 4 sessions;
·; 6 patients have been dosed so far, suffering from either breast cancer, lung cancer and bladder cancer and all with metastasis;
·; No serious drug-related adverse events have so far been reported; and
·; 2 patients have already been rated as having stabilised disease.
ImmuPharma plans to file a US IND in the next few months and to commence a Phase IIb programme the first half of 2011 in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer and pancreatic cancer, which will be confirmed by additional preclinical data.
For further information, please contact:
ImmuPharma PLC:
Dr Robert Zimmer, President & Chief Scientific Officer + 33 389 32 76 50
Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080
Richard Warr, Chairman +44 20 7152 4080
Buchanan Communications
Lisa Baderoon, Mark Court, Jessica Fontaine +44 20 7466 5000
Panmure, Gordon & Co., NOMAD & Broker
Andrew Burnett, Rakesh Sharma +44 20 7459 3600
Execution Noble & Co, Joint Broker
James Bromhead, Richard Crawley +44 20 7456 9191